Fermenta Biotech reports 26% revenue growth in FY26

IIT Madras’s injectable hydrogel could reduce fibrosis treatment cost by 85%

Alkem Labs posts highest-ever EBITDA in FY26; Q4 revenue rises 14.6%

Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit

Supreme Court declares right to trauma care part of Article 21 in landmark judgement

The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually

India’s MedTech industry is entering its defining decade: Dr. Shravan Subramanyam, MD, BPL Medical Technologies

From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies

Solvay and Pantys deepen partnership to expand menstrual health access

Solvay will fund Pantys-led initiatives targeting vulnerable communities through product donations and menstrual health education programs

Indian scientists develop AI-enabled tech for biomedical diagnostic applications

The platform created by NIT Rourkela researchers is capable of delivering rapid, accurate, and repeatable imaging results with minimal human intervention

Remidio’s InstaEyeClinic wins first position at Andhra Pradesh MedTech Innovation Challenge

The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient

Biopharma firms must diversify CDMO partnerships to avoid costly delays: Shilpa Biologicals MD

Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress

Hikal swings back to profit in Q4 FY26 despite regulatory hit & strategic charges

Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments